AstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital
A number of other research firms also recently weighed in on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($72.95) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.09) target price on AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Barclays PLC restated an overweight rating and set a GBX 6,000 ($78.17) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.26) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company’s stock. AstraZeneca plc has an average rating of Hold and an average target price of GBX 5,085.05 ($66.25).
AstraZeneca plc (AZN) opened at 4544.50 on Thursday. The company’s market cap is GBX 57.53 billion. The company’s 50-day moving average price is GBX 5,161.70 and its 200 day moving average price is GBX 4,861.06. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.90) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.
In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($56.93) per share, with a total value of £1,704.30 ($2,220.30).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.